

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Human papillomavirus vaccination: the population... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/6-866/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/6-866" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Human papillomavirus vaccination: the population impact" />
    
            <meta name="og:title" content="F1000Research Article: Human papillomavirus vaccination: the population impact.">
            <meta name="og:description" content="Read the latest article version by Lai-yang Lee, Suzanne M. Garland, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="11527">
            <meta name="article-id" content="10691">
            <meta name="dc.title" content="Human papillomavirus vaccination: the population impact">
            <meta name="dc.description" content="We&amp;nbsp;currently&amp;nbsp;have&amp;nbsp;the knowledge and experience&amp;nbsp;to prevent much of human papillomavirus (HPV)-related disease burden globally. In many countries where prophylactic&amp;nbsp;HPV vaccination programs&amp;nbsp;have been adopted as highly effective public health programs with good vaccine coverage, we are already seeing, in real-world settings, reduction of vaccine-related HPV-type infections, genital warts and cervical pre-cancers with potential reductions in vulvar, vaginal and anal pre-cancers. Moreover, we are seeing a change in cervical screening paradigms, as HPV-based&amp;nbsp;screening&amp;nbsp;programs now&amp;nbsp;have strong evidence to support their use&amp;nbsp;as more sensitive ways to detect underlying cervical&amp;nbsp;abnormalities, as compared with conventional cervical cytology. This article describes the impact of prophylactic vaccination on these outcomes and in settings where these vaccines have been implemented in national immunisation programs. Given the successes seen to date and the availability of essential tools, there has been a global push to ensure that every woman has access to effective cervical screening and every girl has the opportunity for primary prevention through vaccination. A gender-neutral approach by offering vaccination to young boys has also been adopted by some countries and is worthy of consideration given that HPV-related cancers also affect males. Furthermore, vaccination of young boys has the advantage of reducing the risk of HPV transmission to sexual partners, lowering the infectious pool of HPV in the general population and ultimately HPV-related diseases for both genders. Therefore, it is appropriate that all countries&amp;nbsp;consider and promote&amp;nbsp;national guidelines and programs to prevent HPV-related diseases.">
            <meta name="dc.subject" content="HPV vaccination, prophylactics, cervical cancer, prevention ">
            <meta name="dc.creator" content="Lee, Lai-yang">
            <meta name="dc.creator" content="Garland, Suzanne M.">
            <meta name="dc.date" content="2017/06/12">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.10691.1">
            <meta name="dc.source" content="F1000Research 2017 6:866">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="HPV vaccination ">
            <meta name="prism.keyword" content=" prophylactics ">
            <meta name="prism.keyword" content=" cervical cancer ">
            <meta name="prism.keyword" content=" prevention ">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2017/06/12">
            <meta name="prism.volume" content="6">
            <meta name="prism.number" content="866">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.10691.1">
            <meta name="prism.url" content="https://f1000research.com/articles/6-866">
            <meta name="citation_title" content="Human papillomavirus vaccination: the population impact">
            <meta name="citation_abstract" content="We&amp;nbsp;currently&amp;nbsp;have&amp;nbsp;the knowledge and experience&amp;nbsp;to prevent much of human papillomavirus (HPV)-related disease burden globally. In many countries where prophylactic&amp;nbsp;HPV vaccination programs&amp;nbsp;have been adopted as highly effective public health programs with good vaccine coverage, we are already seeing, in real-world settings, reduction of vaccine-related HPV-type infections, genital warts and cervical pre-cancers with potential reductions in vulvar, vaginal and anal pre-cancers. Moreover, we are seeing a change in cervical screening paradigms, as HPV-based&amp;nbsp;screening&amp;nbsp;programs now&amp;nbsp;have strong evidence to support their use&amp;nbsp;as more sensitive ways to detect underlying cervical&amp;nbsp;abnormalities, as compared with conventional cervical cytology. This article describes the impact of prophylactic vaccination on these outcomes and in settings where these vaccines have been implemented in national immunisation programs. Given the successes seen to date and the availability of essential tools, there has been a global push to ensure that every woman has access to effective cervical screening and every girl has the opportunity for primary prevention through vaccination. A gender-neutral approach by offering vaccination to young boys has also been adopted by some countries and is worthy of consideration given that HPV-related cancers also affect males. Furthermore, vaccination of young boys has the advantage of reducing the risk of HPV transmission to sexual partners, lowering the infectious pool of HPV in the general population and ultimately HPV-related diseases for both genders. Therefore, it is appropriate that all countries&amp;nbsp;consider and promote&amp;nbsp;national guidelines and programs to prevent HPV-related diseases.">
            <meta name="citation_description" content="We&amp;nbsp;currently&amp;nbsp;have&amp;nbsp;the knowledge and experience&amp;nbsp;to prevent much of human papillomavirus (HPV)-related disease burden globally. In many countries where prophylactic&amp;nbsp;HPV vaccination programs&amp;nbsp;have been adopted as highly effective public health programs with good vaccine coverage, we are already seeing, in real-world settings, reduction of vaccine-related HPV-type infections, genital warts and cervical pre-cancers with potential reductions in vulvar, vaginal and anal pre-cancers. Moreover, we are seeing a change in cervical screening paradigms, as HPV-based&amp;nbsp;screening&amp;nbsp;programs now&amp;nbsp;have strong evidence to support their use&amp;nbsp;as more sensitive ways to detect underlying cervical&amp;nbsp;abnormalities, as compared with conventional cervical cytology. This article describes the impact of prophylactic vaccination on these outcomes and in settings where these vaccines have been implemented in national immunisation programs. Given the successes seen to date and the availability of essential tools, there has been a global push to ensure that every woman has access to effective cervical screening and every girl has the opportunity for primary prevention through vaccination. A gender-neutral approach by offering vaccination to young boys has also been adopted by some countries and is worthy of consideration given that HPV-related cancers also affect males. Furthermore, vaccination of young boys has the advantage of reducing the risk of HPV transmission to sexual partners, lowering the infectious pool of HPV in the general population and ultimately HPV-related diseases for both genders. Therefore, it is appropriate that all countries&amp;nbsp;consider and promote&amp;nbsp;national guidelines and programs to prevent HPV-related diseases.">
            <meta name="citation_keywords" content="HPV vaccination, prophylactics, cervical cancer, prevention ">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Lai-yang Lee">
            <meta name="citation_author_institution" content="Department of Microbiology and Infectious Diseases, Royal Women&rsquo;s Hospital, Parkville, Victoria, Australia">
            <meta name="citation_author_institution" content="Department of Microbiology, Royal Children&rsquo;s Hospital, Parkville, Victoria, Australia">
            <meta name="citation_author" content="Suzanne M. Garland">
            <meta name="citation_author_institution" content="Department of Microbiology and Infectious Diseases, Royal Women&rsquo;s Hospital, Parkville, Victoria, Australia">
            <meta name="citation_author_institution" content="Department of Microbiology, Royal Children&rsquo;s Hospital, Parkville, Victoria, Australia">
            <meta name="citation_author_institution" content="Department of Infection and Immunity, Murdoch Childrens Research Institute, Royal Children&rsquo;s Hospital, Victoria, Australia">
            <meta name="citation_author_institution" content="Department of Obstetrics Gynaecology, University of Melbourne, Parkville, Victoria, Australia">
            <meta name="citation_publication_date" content="2017/06/12">
            <meta name="citation_volume" content="6">
            <meta name="citation_publication_number" content="866">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.10691.1">
            <meta name="citation_firstpage" content="866">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/6-866/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/6-866.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=11527 /> <input type=hidden id=articleId name=articleId value=10691 /> <input type=hidden id=xmlUrl value="/articles/6-866/v1/xml"/> <input type=hidden id=xmlFileName value="-6-866-v1.xml"> <input type=hidden id=article_uuid value=2d06b23c-e05e-43da-84b4-ced3fc92334c /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Human papillomavirus vaccination: the population impact"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.10691.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.10691.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/6-866"
  },
  "headline": "Human papillomavirus vaccination: the population impact",
  "datePublished": "2017-06-12T10:09:13",
  "dateModified": "2017-06-12T10:09:13",
  "author": [
    {
      "@type": "Person",
      "name": "Lai-yang Lee"
    },    {
      "@type": "Person",
      "name": "Suzanne M. Garland"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "We currently have the knowledge and experience to prevent much of human papillomavirus (HPV)-related disease burden globally. In many countries where prophylactic HPV vaccination programs have been adopted as highly effective public health programs with good vaccine coverage, we are already seeing, in real-world settings, reduction of vaccine-related HPV-type infections, genital warts and cervical pre-cancers with potential reductions in vulvar, vaginal and anal pre-cancers. Moreover, we are seeing a change in cervical screening paradigms, as HPV-based screening programs now have strong evidence to support their use as more sensitive ways to detect underlying cervical abnormalities, as compared with conventional cervical cytology. This article describes the impact of prophylactic vaccination on these outcomes and in settings where these vaccines have been implemented in national immunisation programs. Given the successes seen to date and the availability of essential tools, there has been a global push to ensure that every woman has access to effective cervical screening and every girl has the opportunity for primary prevention through vaccination. A gender-neutral approach by offering vaccination to young boys has also been adopted by some countries and is worthy of consideration given that HPV-related cancers also affect males. Furthermore, vaccination of young boys has the advantage of reducing the risk of HPV transmission to sexual partners, lowering the infectious pool of HPV in the general population and ultimately HPV-related diseases for both genders. Therefore, it is appropriate that all countries consider and promote national guidelines and programs to prevent HPV-related diseases."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/6-866/v1",
            "name": "Human papillomavirus vaccination: the population impact"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Human papillomavirus vaccination: the population impact </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=11527 data-id=10691 data-downloads="" data-views="" data-scholar="10.12688/f1000research.10691.1" data-recommended="" data-doi="10.12688/f1000research.10691.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/6-866/v1/pdf?article_uuid=2d06b23c-e05e-43da-84b4-ced3fc92334c" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-10691-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-10691-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-10691-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Lee Ly and Garland SM. Human papillomavirus vaccination: the population impact [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):866 (<a class=new-orange href="https://doi.org/10.12688/f1000research.10691.1" target=_blank>https://doi.org/10.12688/f1000research.10691.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-10691-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=10691 id=track-article-signin-10691 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/10691?target=/articles/6-866/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=11527 /> <input name=articleId type=hidden value=10691 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Human papillomavirus vaccination: the population impact</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Lai-yang Lee<sup>1,2</sup>,&nbsp;</span><span class=""><a href="mailto:Suzanne.garland@thewomens.org.au" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Suzanne M. Garland</span></a><sup>1-4</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Lai-yang Lee<sup>1,2</sup>,&nbsp;</span><span class=""><a href="mailto:Suzanne.garland@thewomens.org.au" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Suzanne M. Garland</span></a><sup>1-4</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 12 Jun 2017 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.10691.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Microbiology and Infectious Diseases, Royal Women&rsquo;s Hospital, Parkville, Victoria, Australia<br/> <sup>2</sup> Department of Microbiology, Royal Children&rsquo;s Hospital, Parkville, Victoria, Australia<br/> <sup>3</sup> Department of Infection and Immunity, Murdoch Childrens Research Institute, Royal Children&rsquo;s Hospital, Victoria, Australia<br/> <sup>4</sup> Department of Obstetrics Gynaecology, University of Melbourne, Parkville, Victoria, Australia<br/> <p> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=23010-22834></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=23012-22836></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=23011-22835></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> We&nbsp;currently&nbsp;have&nbsp;the knowledge and experience&nbsp;to prevent much of human papillomavirus (HPV)-related disease burden globally. In many countries where prophylactic&nbsp;HPV vaccination programs&nbsp;have been adopted as highly effective public health programs with good vaccine coverage, we are already seeing, in real-world settings, reduction of vaccine-related HPV-type infections, genital warts and cervical pre-cancers with potential reductions in vulvar, vaginal and anal pre-cancers. Moreover, we are seeing a change in cervical screening paradigms, as HPV-based&nbsp;screening&nbsp;programs now&nbsp;have strong evidence to support their use&nbsp;as more sensitive ways to detect underlying cervical&nbsp;abnormalities, as compared with conventional cervical cytology. This article describes the impact of prophylactic vaccination on these outcomes and in settings where these vaccines have been implemented in national immunisation programs. Given the successes seen to date and the availability of essential tools, there has been a global push to ensure that every woman has access to effective cervical screening and every girl has the opportunity for primary prevention through vaccination. A gender-neutral approach by offering vaccination to young boys has also been adopted by some countries and is worthy of consideration given that HPV-related cancers also affect males. Furthermore, vaccination of young boys has the advantage of reducing the risk of HPV transmission to sexual partners, lowering the infectious pool of HPV in the general population and ultimately HPV-related diseases for both genders. Therefore, it is appropriate that all countries&nbsp;consider and promote&nbsp;national guidelines and programs to prevent HPV-related diseases. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> HPV vaccination, prophylactics, cervical cancer, prevention </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Suzanne M. Garland (<a href="mailto:Suzanne.garland@thewomens.org.au">Suzanne.garland@thewomens.org.au</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Suzanne M. Garland </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> SG has received speaking fees from Merck Sharp &amp; Dohme (MSD) and Sanofi Pasteur MSD for work performed in her personal time. Merck paid for her travel and accommodation to present at HPV Advisory Board meetings. Lai-yang Lee declares that she has no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> SG has received grants to her institution from the Commonwealth Department of Health for HPV genoprevalence surveillance post-vaccination, Merck and GlaxoSmithKline to perform phase 3 clinical vaccine trials, Merck to evaluate HPV in RRP post-vaccination program, Seqirus Australia for funding of the Australian Cervical Cancer Typing Study, and the Victoria Cancer Agency for a study on monitoring and effectiveness of the Australian cervical cancer program, a translation to reduction in vaccine-related HPV infection and pre-cancerous cervical lesions study (the Vaccine Against Cervical Cancer Impact and Effectiveness study) plus a study on associations and typing of early-onset cancers in young women. <br/> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp;  2017 Lee Ly and Garland SM. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Lee Ly and Garland SM. Human papillomavirus vaccination: the population impact [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):866 (<a href="https://doi.org/10.12688/f1000research.10691.1" target=_blank>https://doi.org/10.12688/f1000research.10691.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 12 Jun 2017, <b>6</b>(F1000 Faculty Rev):866 (<a href="https://doi.org/10.12688/f1000research.10691.1" target=_blank>https://doi.org/10.12688/f1000research.10691.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 12 Jun 2017, <b>6</b>(F1000 Faculty Rev):866 (<a href="https://doi.org/10.12688/f1000research.10691.1" target=_blank>https://doi.org/10.12688/f1000research.10691.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d7882e215>Introduction</h2><div class=section><a name=d7882e218 class=n-a></a><h3 class=section-title>Human papillomavirus infection and disease association</h3><p class="" id=d7882e223>Human papillomavirus (HPV) is the commonest sexually transmitted infection, and the resultant diseases have significant morbidity and mortality<sup><a href="#ref-1">1</a></sup>. Although most HPV infections are transient, persistent infections are a prerequisite for pre-cancerous lesions and ultimately cancer.<sup><a href="#ref-2">2</a><a href="#ref-5">5</a></sup>. It is highly likely that latent infection (as infection dormant in the basal cells not readily detectable by diagnostic assays, but reversible)<sup><a href="#ref-6">6</a></sup> or subclinical infections (or both) exist and this is particularly relevant when an individual is immunocompromised since it increases the risk of developing symptomatic disease. Oncogenic HPVs were shown by Harald zur Hausen to be the causative agent of cervical cancer in the early 1980s by virtue of molecular epidemiology; for this work, zur Hausen shared the Nobel Prize in Physiology or Medicine in 2008<sup><a href="#ref-7">7</a></sup>. Of the many genotypes specifically infecting the anogenital area, HPV16 and HPV18 are the commonest high-risk or oncogenic genotypes in cervical cancer and are responsible for approximately 50% of high-grade cervical dysplasias and 70% of cases of cervical cancer, the fourth most common cancer in females globally<sup><a href="#ref-8">8</a>,<a href="#ref-9">9</a></sup>. Oncogenic HPVs cause almost 100% of cervical cancers, 90% of anal, 70% of vaginal, 40% of vulvar, 50% of penile and 13% to 72% of oropharyngeal cancers, and HPV16 predominates in all of these non-cervical HPV-related cancers. HPV6 and HPV11, which are classified as low-risk genotypes, cause 90% of genital warts as well as the rare but debilitating recurrent respiratory papillomatosis (RRP)<sup><a href="#ref-10">10</a>,<a href="#ref-11">11</a></sup>.</p></div><div class=section><a name=d7882e261 class=n-a></a><h3 class=section-title>Prophylactic human papillomavirus vaccines</h3><p class="" id=d7882e266>Given the heavy disease burden of cervical cancer, prophylactic HPV vaccines were developed to target the commonest high- and low-risk HPV genotypes. Two such vaccines were first licensed for clinical use in 2006 following phase 3 clinical trials, which showed efficacy, safety and immunogenicity against vaccine-related HPV types<sup><a href="#ref-12">12</a><a href="#ref-15">15</a></sup>. Currently available vaccines now include bivalent (2vHPV and targets HPV 16/18)<sup><a href="#ref-12">12</a>,<a href="#ref-13">13</a></sup>, quadrivalent (4vHPV and targets HPV 16/18/6/11)<sup><a href="#ref-14">14</a>,<a href="#ref-15">15</a></sup> and nonavalent (targets HPV 16/18/6/11 as well as the five next most common oncogenic types found in cervical cancers, 31/33/45/52/58) vaccines<sup><a href="#ref-16">16</a></sup>. Whilst many countries have licensed these vaccines, worldwide introduction into national immunisation programs differs by country, and some vaccines are available only on a user-pays basis and therefore entail an out-of-pocket expense. This has contributed to the resultant generally poor and inequitable uptake. For the greatest impact of these vaccines, the aim is to vaccinate adolescent females prior to sexual debut and to gain high coverage of the target population<sup><a href="#ref-9">9</a></sup>. Some countries have implemented catch-up programs for older females or routine vaccination of adolescent males (or both) to increase overall population coverage and enhance herd protection<sup><a href="#ref-17">17</a></sup>.</p></div><div class=section><a name=d7882e304 class=n-a></a><h3 class=section-title>Vaccine effectiveness and impact</h3><p class="" id=d7882e309>Clinical trials indicated efficacy of the vaccines against the HPV types included in the respective vaccines as well as some modest cross-protection against some non-vaccine but phylogenetically related strains (HPV 31, 33 for HPV16-related types and HPV45 for 18-related types)<sup><a href="#ref-12">12</a>,<a href="#ref-18">18</a></sup>. The true benefit of vaccination can be seen only from real-life impact and effectiveness once vaccination has been included in public health programs. To appreciate this requires good surveillance and observation of changes in genoprevalence within vaccine-eligible age cohorts as well as of disease outcomes. Some of the challenges here have included the fact that HPV cannot be cultured by traditional means, so DNA typing in the general community before and after vaccination is required to determine molecular genoprevalence. Although a number of assays to determine the presence of HPV are currently available<sup><a href="#ref-19">19</a></sup>, their appropriateness is based on whether they are meant to be used for clinical needs (to detect underlying disease in which case assays are designed with clinical cut-offs and are less sensitive) or for pure epidemiological purposes (these use analytical viral endpoints and are highly sensitive)<sup><a href="#ref-20">20</a>,<a href="#ref-21"> 21</a></sup>. Furthermore, as HPV infection is not notifiable, nor are many of the associated clinical manifestations in most countries, individual surveillance systems have been required to measure the impact and effectiveness of the vaccines. In addition, as the times from infection to the various disease manifestations differ and may be weeks to months (genital warts) to years (pre-cancers) or decades (cancer), the impact of vaccination on each disease varies. Consequently, in the 10 years since the introduction of both 4vHPV and 2vHPV vaccines, measures of vaccine impact have largely been determined by individual observational studies in countries with higher vaccine coverage, although a number of large, countrywide surveillance activities are now occurring. Thus, a direct comparison between the multiple studies published to date is complicated as the population studied, the duration of study and the endpoints observed or measured (or both) differ. Monitoring impact is difficult, particularly as some endpoints such as pre-cancerous lesions require a robust pre-cancer screening program to be in place or are not notifiable or have a prolonged interval between infection and development of diseases, particularly for cancers which usually occur after decades of persistent infection with a high-risk HPV type.</p><p class="" id=d7882e330>In this article, we define vaccine impact as the effect of public health programs of HPV vaccines at a population level and the measurement thereof of reduction in disease burden (before and after initiation of a vaccination program) and largely focus on this. In contrast, vaccine effectiveness is examined at an individual level<sup><a href="#ref-22">22</a></sup>. It is largely observational and determines the effect of vaccination observed in populations after a program commences and compares outcomes in those vaccinated with those unvaccinated.</p><p class="" id=d7882e337>Vaccine impact will be determined by the type of vaccine program (an ongoing routine vaccination program to a specific age group versus inclusion of a catch-up program which may be limited in time and/or target a narrow or wide number of age cohorts), vaccine coverage, which population is targeted (for example, a program focused entirely on females, a gender-neutral approach, or targeted vaccination such as the HIV-positive population), the duration of vaccine protection, the duration of follow-up after vaccination, and type of surveillance, if any, of various outcome measures.</p></div><div class=section><a name=d7882e341 class=n-a></a><h3 class=section-title>Vaccine impact on human papillomavirus infection</h3><p class="" id=d7882e346>Australia was one of the first countries to implement a fully government-funded, population-based HPV vaccination program. It commenced in 2007 as an ongoing school-based program with a three-dose course of the 4vHPV vaccine, targeting females in the first year of high school at age 12 to 13 years, with a catch-up for those ages 12 to 26 years until December 2009<sup><a href="#ref-23">23</a></sup>. In 2013, the Australian government extended the program to include 12- to 13-year-old males, including a 2-year catch-up vaccination program for those ages 14 to 15 years<sup><a href="#ref-24">24</a>, <a href="#ref-25">25</a></sup>. Overall, the program has been well received and high vaccine coverage rates have been achieved; the greatest rates have been from those within the school-based cohorts: over 70% have received all three doses for young girls and just under 70% have received all three doses for boys<sup><a href="#ref-24">24</a><a href="#ref-26">26</a></sup>. Consequently, Australian researchers were among the first to report reductions in the prevalence of vaccine-type HPV infections, by 86% in 18- to 24-year-olds who had received three vaccine doses and 76% for those who had received one or two doses<sup><a href="#ref-22">22</a>,<a href="#ref-27">27</a>,<a href="#ref-28">28</a></sup>. In general, Tabrizi <i>et al</i>. found that the greatest decline in vaccine-type HPV prevalence corresponded to the age group which had the highest vaccine coverage, even in the unvaccinated but eligible-age population, highly suggestive of herd protection<sup><a href="#ref-28">28</a></sup>. Furthermore, Australia is already seeing herd protection in young males as a result of the female program<sup><a href="#ref-29">29</a></sup>.</p><p class="" id=d7882e389>Other countries that have achieved high coverage with 4vHPV or 2vHPV vaccines also report rapid and large declines in vaccine-related HPV infections. For example, in Scotland, which also has a school-based program, which targets 12- to 13-year-old girls as an ongoing program and had a limited 3-year catch-up from 2008 to 2011 for 13- to 17-year-olds, coverage rates for the 2vHPV vaccine have been even greater, at up to 90%, and reported declines in vaccine-related infections were from 29.8% to 13.6%<sup><a href="#ref-30">30</a></sup>. In contrast, in the USA, coverage of the 4vHPV vaccine has been much lower, at 40% for females and 22% for males; yet despite this, national impact studies from the USA 4 years after the introduction of HPV vaccines noted a 56% decrease in HPV vaccine types (from cervical-vaginal samples from 14- to 19-year-olds)<sup><a href="#ref-31">31</a>,<a href="#ref-32">32</a></sup>. Although the early vaccination initiation uptake rate was low (at 17%) for females 19 to 26 years old in 2009, by 2012 the uptake in the USA had doubled to 34%, resulting in a further 45% decrease in the prevalence of vaccine-type HPV<sup><a href="#ref-33">33</a></sup>, or an overall 64% decrease in vaccine-type HPV prevalence after 6 years<sup><a href="#ref-32">32</a></sup>. A less marked, but still significant, reduction of 34% prevalence over the same time frame was noted in the 20- to 24-year-old group<sup><a href="#ref-32">32</a></sup>. In sexually active US women ages 14 to 24 in the post-vaccination era, those who had received at least one HPV vaccine dose had a 2.1% reduction of vaccine-type HPV prevalence compared with 16.9% in the same age group of unvaccinated women<sup><a href="#ref-32">32</a></sup>.</p></div><div class=section><a name=d7882e422 class=n-a></a><h3 class=section-title>Genital warts</h3><p class="" id=d7882e427>Genital warts are a common condition, which affects up to 10% of the female population under 45 years old and which usually develops 2 to 3 months after infection with low-risk HPV genotypes, primarily HPV 6 and 11<sup><a href="#ref-10">10</a>,<a href="#ref-34">34</a></sup>. Australia was the first to report a reduction in genital warts, and the reduction was larger and faster than had been expected by researchers<sup><a href="#ref-35">35</a>,<a href="#ref-36">36</a></sup>, and the 4vHPV vaccine provided up to 92% reduction in HPV-associated genital warts<sup><a href="#ref-37">37</a></sup>. Interestingly, observations from early use of 2vHPV vaccines noted an unexpected decrease in genital warts. It is speculated that this response is due to vaccination resulting in a cell-mediated immune response which confers a moderate amount of protection against some low-risk HPV types<sup><a href="#ref-38">38</a>,<a href="#ref-39">39</a></sup>.</p><p class="" id=d7882e455>Since the commencement of 4vHPV vaccination, there has been a substantial reduction in reports of genital warts in countries with 4vHPV vaccination programs (<a href="#T1">Table 1</a>)<sup><a href="#ref-35">35</a><a href="#ref-37">37</a>,<a href="#ref-40">40</a><a href="#ref-43">43</a></sup>. A Belgian study noted a decrease of 8.1% in genital warts in the general population, and the highest decreases were in 16- to 22-year-old males and females between the pre- and post-vaccine era<sup><a href="#ref-44">44</a></sup>. Australia, with its high vaccine coverage rates, reported the greatest worldwide decline, of up to 92% in the under-21 age group<sup><a href="#ref-37">37</a></sup>. Several studies have highlighted that the greatest efficacy of vaccination against genital warts was when the first dose of vaccine was given at a younger age<sup><a href="#ref-44">44</a></sup> with less of an effect at an older age<sup><a href="#ref-40">40</a></sup>.</p><div class="table-wrap panel clearfix"><a name=T1 class=n-a></a><div class=caption><h3>Table 1. Summary of human papillomavirus vaccination programs, outcomes and cervical screening programs.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d7882e502 class=n-a></a><thead><a name=d7882e504 class=n-a></a><tr><a name=d7882e506 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d7882e508 class=n-a></a></th><th align=left colspan=1 rowspan=1 valign=top><a name=d7882e510 class=n-a></a>Australia</th><th align=left colspan=1 rowspan=1 valign=top><a name=d7882e513 class=n-a></a>USA</th><th align=left colspan=1 rowspan=1 valign=top><a name=d7882e516 class=n-a></a>United Kingdom</th><th align=left colspan=1 rowspan=1 valign=top><a name=d7882e519 class=n-a></a>Denmark</th><th align=left colspan=1 rowspan=1 valign=top><a name=d7882e523 class=n-a></a>Scotland</th></tr></thead><tbody><a name=d7882e528 class=n-a></a><tr><a name=d7882e530 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e532 class=n-a></a>Delivery route</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e535 class=n-a></a>School</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e538 class=n-a></a>Clinic</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e541 class=n-a></a>Mostly school</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e544 class=n-a></a>Clinic</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e548 class=n-a></a>School</td></tr><tr><a name=d7882e552 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e554 class=n-a></a>HPV vaccine program<br class=br>commencement</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e559 class=n-a></a>2007</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e562 class=n-a></a>2006</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e565 class=n-a></a>2008</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e568 class=n-a></a>2009</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e572 class=n-a></a>2008</td></tr><tr><a name=d7882e576 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e578 class=n-a></a>Vaccine type</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e581 class=n-a></a>4vHPV<br class=br>Ongoing</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e586 class=n-a></a>4vHPV<br class=br>2006-2016<br class=br><br class=br>9vHPV<br class=br>December 2016</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e596 class=n-a></a>2vHPV<br class=br>2008-2012<br class=br><br class=br>4vHPV 2012</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e604 class=n-a></a>4vHPV</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e608 class=n-a></a>2vHPV<br class=br>2008-2012<br class=br><br class=br>4vHPV 2012</td></tr><tr><a name=d7882e617 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e619 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;Three-dose schedule</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e622 class=n-a></a>Yes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e625 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e627 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e629 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e632 class=n-a></a></td></tr><tr><a name=d7882e635 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e637 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;Two-dose schedule<sup><a href="#TFN1">a</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e643 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e646 class=n-a></a>Yes October 2016</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e649 class=n-a></a>Yes September<br class=br>2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e654 class=n-a></a>Yes 2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e658 class=n-a></a>Yes 2014</td></tr><tr><a name=d7882e663 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e665 class=n-a></a>Females</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e668 class=n-a></a>Yes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e671 class=n-a></a>Yes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e674 class=n-a></a>Yes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e677 class=n-a></a>Yes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e681 class=n-a></a>Yes</td></tr><tr><a name=d7882e685 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e687 class=n-a></a>Target age, years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e690 class=n-a></a>12-13</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e693 class=n-a></a>11-12</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e696 class=n-a></a>12-13</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e699 class=n-a></a>12</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e703 class=n-a></a>12-13</td></tr><tr><a name=d7882e707 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e709 class=n-a></a>Males (routine)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e712 class=n-a></a>Yes from 2013</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e715 class=n-a></a>Yes from 2011</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e718 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e721 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e725 class=n-a></a>No</td></tr><tr><a name=d7882e729 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e731 class=n-a></a>Target age males,<br class=br>years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e736 class=n-a></a>12-13</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e739 class=n-a></a>11-12</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e742 class=n-a></a>-</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e745 class=n-a></a>-</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e749 class=n-a></a>-</td></tr><tr><a name=d7882e753 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e755 class=n-a></a>Catch-up program</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e758 class=n-a></a>12-26 <br class=br>2007-2009<br class=br><br class=br>14-15 years old <br class=br>2013-2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e768 class=n-a></a>13-26 <br class=br>Ongoing<br class=br><br class=br></td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e775 class=n-a></a>Up to 18 <br class=br>2009-2011</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e780 class=n-a></a>13 -15 <br class=br>2009<br class=br><br class=br>2nd catch-up<br class=br>20-27  2012</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e791 class=n-a></a>13-17 <br class=br>2008-2011</td></tr><tr><a name=d7882e797 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e799 class=n-a></a>Estimated coverage</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e802 class=n-a></a>2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e805 class=n-a></a>2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e808 class=n-a></a>2013/2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e811 class=n-a></a>2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e815 class=n-a></a></td></tr><tr><a name=d7882e819 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e821 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;Three doses</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e824 class=n-a></a>77.4% <br class=br>66.4% </td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e829 class=n-a></a>41.9% <br class=br>28.1% </td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e834 class=n-a></a>86.7%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e837 class=n-a></a>82%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e841 class=n-a></a>12-13 years old 90%<br class=br>Catch-up cohort 66%<br class=br></td></tr><tr><a name=d7882e848 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e850 class=n-a></a>&nbsp;&nbsp;&nbsp;&nbsp;At least one dose</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e853 class=n-a></a>85.6% <br class=br>77% </td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e858 class=n-a></a>62.8% <br class=br>49.8% </td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e863 class=n-a></a>91.1%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e866 class=n-a></a>90%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e870 class=n-a></a>&gt;90%</td></tr><tr><a name=d7882e874 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e876 class=n-a></a>Vaccine-type HPV<br class=br>infection reduction</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e881 class=n-a></a>18-26 years old<br class=br>3x dose 86%<br class=br><br class=br>2x dose 76%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e889 class=n-a></a>2010<br class=br>14-19  56%<br class=br><br class=br>2012<br class=br>14-19 years old  64%<br class=br>20-24  34%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e901 class=n-a></a>16-18 years old<br class=br>HPV 16/18<br class=br>prevalence reduce<br class=br>from 19.1% to 6.5%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e910 class=n-a></a>Not available</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e914 class=n-a></a>HPV 16/18<br class=br>prevalence reduce<br class=br>from 29.8% to 13.6%</td></tr><tr><a name=d7882e922 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e924 class=n-a></a>Genital warts (types<br class=br> 6/11)<br class=br>Reduction</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e931 class=n-a></a>Up to 92%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e934 class=n-a></a>&lt;21 years old 34.8%<br class=br><br class=br>&gt;21 years old 10%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e940 class=n-a></a>2vHPV<br class=br>20.8%<br class=br><br class=br>4vHPV-<br class=br>38.9% <br class=br>30.2% </td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e952 class=n-a></a>2013<br class=br>&lt;18  up to 55.1%<br class=br><br class=br>&lt;18 years old  up<br class=br>to 36.6%<br class=br></td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e964 class=n-a></a>Since 4vHPV vaccine<br class=br>use, decline in wart<br class=br>prescription (personal<br class=br>communication, Kevin<br class=br>Pollock, 5 January<br class=br>2017)</td></tr><tr><a name=d7882e978 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e980 class=n-a></a>CIN/<br class=br>Adenocarcinoma<br class=br>Reduction</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e987 class=n-a></a>Low-grade<br class=br>34%<br class=br><br class=br>High-grade<br class=br>47%<br class=br><br class=br>&lt;20 years old 54%<br class=br><br class=br>20-24 years old 37%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e1004 class=n-a></a>HPV16/18 CIN2+<br class=br><br class=br>vaccinated &gt;24<br class=br>months before<br class=br>PAP versus<br class=br>unvaccinated<br class=br>, adjusted<br class=br>prevalence ratio of<br class=br>0.67</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e1023 class=n-a></a>Not available</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e1026 class=n-a></a>Atypia<br class=br>&lt;18 years old<br class=br>33.4% (annual<br class=br>percentage)<br class=br>18-20 years old<br class=br>12.6%<br class=br><br class=br>CIN2+<br class=br>18-20 years old<br class=br>14%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e1048 class=n-a></a>CIN1 29%<br class=br>CIN2 50%<br class=br>CIN3 55%</td></tr><tr><a name=d7882e1056 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e1058 class=n-a></a>Screening program:<br class=br>Type and interval age<br class=br>commencement</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e1065 class=n-a></a>Cervical cytology<br class=br><br class=br>18-69 every 2 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e1071 class=n-a></a>Cervical cytology<br class=br><br class=br>21-65 every 3 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e1077 class=n-a></a>Cervical cytology<br class=br><br class=br>25-49 every 3 years<br class=br><br class=br>50-64 every 5 years<br class=br><br class=br>January 2016: UK<br class=br>National Screening<br class=br>Committee<br class=br>recommend HPV<br class=br>primary screening<br class=br>(to commence in<br class=br>the near future)<sup><a href="#ref-90">90</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e1105 class=n-a></a>Cervical cytology<br class=br><br class=br>23-49 every 3 years<br class=br><br class=br>50-65 every 5 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e1115 class=n-a></a>Cervical cytology<br class=br><br class=br>25-49 every 3 years<br class=br><br class=br>50-64 every 5 years</td></tr><tr><a name=d7882e1126 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e1128 class=n-a></a>Comments</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e1131 class=n-a></a>1 May 2017 to be<br class=br>changed to HPV<br class=br>DNA every 5 years<br class=br>for 25-74 years old</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e1140 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e1142 class=n-a></a>Since 2014,<br class=br>two-dose schedule<br class=br>&lt;15 years old<br class=br>&gt;15 years old on<br class=br>initiation, three-<br class=br>dose schedule</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e1155 class=n-a></a>Since 2014,<br class=br>two-dose schedule<br class=br>&lt;15 years old<br class=br>&gt;15 years old on<br class=br>initiation, three-dose<br class=br>schedule</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e1169 class=n-a></a>Screening prior to<br class=br>2013, 20-60 years old<br class=br>every 3 years</td></tr><tr><a name=d7882e1177 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e1179 class=n-a></a>Additional references</td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e1182 class=n-a></a><sup><a href="#ref-25">25</a>,<a href="#ref-91">91</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e1190 class=n-a></a><sup><a href="#ref-92">92</a><a href="#ref-96">96</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e1198 class=n-a></a><sup><a href="#ref-97">97</a><a href="#ref-100">100</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e1206 class=n-a></a><sup><a href="#ref-101">101</a>, <a href="#ref-102">102</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d7882e1215 class=n-a></a><sup><a href="#ref-103">103</a>, <a href="#ref-104">104</a></sup><br class=br></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=TFN1 class=n-a></a><p id=d7882e1231> <sup>a</sup>Less than 15 years at the time of first dose: two-dose regimen of a prime and a boost separated by a minimum of 6 months<sup><a href="#ref-73">73</a></sup>.</p></div><div class=footnote><a name=TFN2 class=n-a></a><p id=d7882e1243> 2vHPV, bivalent human papillomavirus vaccine; 4vHPV, quadrivalent human papillomavirus vaccine; 9vHPV, nonavalent human papillomavirus vaccine; CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; PAP, Papanicolaou test.</p></div></div></div></div><div class=section><a name=d7882e1250 class=n-a></a><h3 class=section-title>Cervical cytology and histological abnormalities</h3><p class="" id=d7882e1255>Genital warts have a short incubation period and hence this was the first disease reduction noted from vaccination. The second disease outcome to see reductions was cervical dysplasia, which has an intermediate incubation period (peak age of 26 to 30 years)<sup><a href="#ref-45">45</a></sup>. Again, this was first reported in an ecological study in Victoria, Australia<sup><a href="#ref-46">46</a></sup> and was made possible because Australia had a HPV vaccine register, comprehensive cervical cytology reporting as well as the ability (following legislation) for the registers to be linked. Australias national HPV vaccination programs have led to a 34% decline in low-grade and a 47% decline in high-grade cervical intraepithelial neoplasia (CIN) and adenocarcinoma <i>in situ</i>, and the largest reductions were in the vaccinated younger age group<sup><a href="#ref-22">22</a>,<a href="#ref-47">47</a></sup>. Women under the age of 20 had a prevalence decline from 10.9/1000 screened women to 5.0/1000 over a period of 10 years, and prevalence in 20- to 24-year-olds decreased from 21.5/1000 screened to 13.5/1000 in a similar time period. In the over-30-year-old age group, the prevalence of high-grade CIN has continued to slowly rise<sup><a href="#ref-48">48</a></sup>. Similar declines have been observed in Scotland and Denmark<sup><a href="#ref-49">49</a><a href="#ref-52">52</a></sup> (<a href="#T1">Table 1</a>). There are randomised controlled phase 2/3 trials indicating that, despite diverse populations and geographical locations, HPV vaccines covering HPV16/18 provided some cross-protection against non-vaccine strain HPV and could protect women against cervical and non-cervical HPV-related infections<sup><a href="#ref-53">53</a></sup>.</p></div><div class=section><a name=d7882e1296 class=n-a></a><h3 class=section-title>Cervical cancer</h3><p class="" id=d7882e1301>At present, it is too early to show clinical disease or population-based disease reduction for cervical cancer, as this is a disease peaking in the mid-30s and mid-40s in Australia<sup><a href="#ref-54">54</a></sup>, although the peak has shifted to the late 20s to early 30s in some countries<sup><a href="#ref-55">55</a></sup>. One would expect to see reductions within the next few years in the under-30-year-olds, particularly in those countries with high coverage of catch-up programs extending to 26 years of age, such as Australia and Denmark.</p><p class="" id=d7882e1312>Based on the PATRICIA trial (Papilloma Trial against Cancer in young Adults) of the 2vHPV vaccine, it has been estimated that with 50% vaccine coverage, there could be a worldwide reduction of cervical cancer incidence of 246,086 cases annually but that with 90% coverage, there could be up to 442,955 cases averted<sup><a href="#ref-56">56</a></sup>. With the greater coverage provided by the nonavalent vaccine, it is proposed that with high coverage, 90% to 93% of all cervical cancers would be prevented<sup><a href="#ref-57">57</a>,<a href="#ref-58">58</a></sup>.</p><p class="" id=d7882e1326>The incidence of non-cervical HPV-related cancers is generally low and peaks at a later age compared with cervical cancer<sup><a href="#ref-59">59</a></sup>. Thus, more time and large population-based effectiveness studies with various cancers as endpoints will be required before impact can be determined. There are early data sets currently reviewing the implication of vaccine-type HPV reduction and the effect on persistent anal infections and intraepithelial neoplasia<sup><a href="#ref-60">60</a></sup>.</p></div><div class=section><a name=d7882e1338 class=n-a></a><h3 class=section-title>Impediments and challenges for the future</h3><p class="" id=d7882e1343><b><i>Vaccine uptake and coverage.</i></b> Although the effect of population-wide vaccination has been observed for 10 years, the reported findings may not accurately reflect future impact and this is for several reasons. Some countries have been slow to adopt HPV vaccination or vaccine coverage has been low (or both), even in high-income countries. Vaccine uptake rates in 13- to 17-year-olds in the USA in 2013 were 57% (one dose) and 38% (three doses)<sup><a href="#ref-32">32</a></sup>. In Australia, between 2007 and 2015, vaccine uptake rates were 85.6% (one dose) and 77.4% (three doses) for females turning 15 years of age<sup><a href="#ref-61">61</a></sup>. Successful strategies to increase coverage have included publically supported health promotion and missed-doses catch-up vaccine campaigns<sup><a href="#ref-62">62</a></sup>, client reminders, recall programs, provider assessment and feedback interventions. Low- and middle-income countries often have a high HPV disease burden: however, only 15% of these countries have adopted a vaccination program<sup><a href="#ref-18">18</a></sup>. Focusing on these countries and giving reassurance regarding vaccine safety will substantially impact HPV vaccination rates and outcomes<sup><a href="#ref-63">63</a></sup>.</p><p class="" id=d7882e1369><b><i>Safety.</i></b> Concern regarding vaccine safety is an issue that often arises. The US Centers for Disease Control and Prevention (CDC), through the Vaccine Adverse Event Reporting System, classified only 7% of adverse events as serious from over 90 million doses of HPV vaccines. The CDC found no causal association between HPV vaccines and ovarian failure, Guillain-Barr syndrome or postural orthostatic tachycardia syndrome. Overall, HPV vaccines have a good safety profile, but ongoing monitoring will be required as 9vHPV vaccines have been introduced<sup><a href="#ref-64">64</a><a href="#ref-67">67</a></sup>. In Japan, poor or inappropriate information (or both), including reports on complex regional pain syndrome, has resulted in the government withdrawing support for HPV vaccination programs<sup><a href="#ref-68">68</a><a href="#ref-70">70</a></sup>. Despite comprehensive independent evaluations of safety<sup><a href="#ref-71">71</a>,<a href="#ref-72">72</a></sup>, including endorsement of safety by bodies such as the World Health Organization (WHO)<sup><a href="#ref-73">73</a></sup>, the International Papillomavirus Society<sup><a href="#ref-66">66</a></sup> and the CDC<sup><a href="#ref-74">74</a></sup>, the Japanese government has continued to refuse to re-implement population-wide vaccination<sup><a href="#ref-69">69</a></sup>.</p><p class="" id=d7882e1413><b><i>Ideal age for vaccination.</i></b> In many respects, if the HPV vaccines could be administered in childhood, they could use infrastructure already in place for the Expanded Program on Immunization vaccines, as in general these see high uptake even in those countries with low resources. However, the immunity developed by HPV vaccination needs to be robust for several decades to ensure that infection does not occur when young people become sexually active and therefore to prevent diseases in the longer term. Although some studies have shown detectable neutralising antibodies 10 years after vaccination, there are not yet any data about antibody persistence beyond that<sup><a href="#ref-22">22</a></sup>. It is currently believed that the antibody responses made by the vaccines are strong and long-lasting and that only small titres are in fact required for protection<sup><a href="#ref-75">75</a></sup>.</p><p class="" id=d7882e1427>Over the last 10 years, there have been changes in sexual behaviour, such as lowered median age of sexual debut, increased exposure from the increase in the number of sexual partners, and choice of orientation of sexual partner; however, these trends vary from country to country. The ability of vaccine programs in different countries to be flexible will allow these changes to be accounted for in the future. As shown in <a href="#T1">Table 1</a>, different delivery programs/routes for the vaccines result in different outcomes in different countries. A single worldwide approach is not appropriate, and programs need to be tailored to each countrys population.</p><p class="" id=d7882e1434><b><i>Dosing.</i></b> New information regarding number of doses of vaccine necessary for long-lasting immunity is becoming available. The current WHO recommendation is that with respect to HPV-vaccine-related-type antibody responses, two doses of HPV vaccine for females 9 to 14 years old is non-inferior to three doses in adult women as long as the two doses are at least 6 months apart<sup><a href="#ref-73">73</a></sup>. This decision was based largely on neutralising antibody outcome and more recent findings of reduced HPV-vaccine-type-related disease outcomes, but again good surveillance systems should be able to monitor impact on disease endpoints with longer time intervals from the point of vaccination. Furthermore, this may help to address concerns regarding reduced efficacy<sup><a href="#ref-76">76</a></sup> to ensure that a third dose could be administered if surveillance shows breakthrough disease. For females older than 15 years, those who are immunocompromised or HIV-positive, a three-dose regimen is still recommended<sup><a href="#ref-73">73</a>,<a href="#ref-77">77</a></sup>.</p><p class="" id=d7882e1455><b><i>Gender-neutral approaches.</i></b> Although females have been the primary target of HPV vaccine, extending the program towards males may have some benefit. A 2011 Australian study predicted that, based on the female-only vaccination program, there could be up to a 68% decrease in male HPV infections by 2050 and a 14% decrease in head, neck and anogenital cancers. The effect on oropharyngeal cancers is unclear<sup><a href="#ref-78">78</a></sup>. This prediction is based on heterosexual relationships offering herd protection. A high-risk HPV group, men who have sex with men, are less likely to benefit from a female-only vaccination program<sup><a href="#ref-79">79</a></sup>. A gender-neutral approach may not only reduce HPV-related diseases in males but also reduce the infection and transmission to females, ultimately reducing the pool of infectious virus in a community. Male vaccination would confer an even greater benefit in settings where female vaccination rates are low. Hence, vaccination of males has recently been incorporated into several national programs. Measuring vaccine effectiveness in the context of gender-neutral programs will bring further challenges<sup><a href="#ref-24">24</a></sup>.</p><p class="" id=d7882e1473><b><i>Multivalent human papillomavirus vaccines.</i></b> Some countries have implemented or have plans to commence the use of 9vHPV vaccines to offer protection against the additional five next most common oncogenic HPV types after HPV 16/18 in an effort to further improve health outcomes. This move is supported by studies which indicate potential cost savings and health benefits that could result from universal nonavalent vaccination programs<sup><a href="#ref-16">16</a>,<a href="#ref-80">80</a>,<a href="#ref-81">81</a></sup>.</p></div><div class=section><a name=d7882e1490 class=n-a></a><h3 class=section-title>Alternative vaccine policies: HPV FASTER potential to impact disease earlier</h3><p class="" id=d7882e1495>Consideration for vaccinating women who are already sexually active but may not have been infected with all HPV types covered in the vaccines could well reduce the burden of disease more rapidly. This concept is based on data from phase 3 trials indicating that 2vHPV and 4vHPV vaccines are efficacious, immunogenic and safe in women ages 26 to 45 years old with a 90% vaccine efficacy in protection against cervical pre-cancer in HPV-DNA-negative women (regardless of serostatus) and 50% vaccine efficacy in women who had previously been exposed to HPV<sup><a href="#ref-82">82</a><a href="#ref-84">84</a></sup>. Moreover, in trials in younger women, it was shown that vaccines were not efficacious when a woman was HPV-positive for a particular type<sup><a href="#ref-85">85</a></sup>, although it was likely for women who were HPV-negative but antibody-positive from natural infection that they would gain efficacy against later disease<sup><a href="#ref-86">86</a>,<a href="#ref-87">87</a></sup>. The importance of a coordinated screening and vaccination program cannot be overlooked and this has prompted the HPV-FASTER concept. This protocol intends to offer women up to the age of 45 years HPV vaccination and incorporates HPV testing after the age of 30 for screening, with ongoing follow-up and early management of high-risk HPV-positive women. Further studies will be required to investigate the acceptability and feasibility of such an approach, most appropriate cut-off age of offering vaccination, ideal screening commencement, cessation and interval times to refine the protocol<sup><a href="#ref-88">88</a></sup>.</p><p class="" id=d7882e1520><b><i>Surveillance.</i></b> A necessary condition for accurately monitoring the impact and effectiveness of vaccine programs is the existence of diligent and ongoing surveillance<sup><a href="#ref-89">89</a></sup>. For HPV, this requires surveillance of HPV vaccination coverage and safety, HPV infection genoprevalence, cervical dysplasia incidence, cervical (as well as other anogenital and oropharyngeal cancer, ideally with genotyping of cancers) cancer registries, as well as surveillance for non-cancer outcomes such as warts and RRPs. Ideally, this would include the ability for the various data sources to be linked. Encouragement in participation in screening programs is essential, particularly as new cervical screening programs that incorporate DNA testing as the primary screen usually have longer intervals between screens compared with those with cervical cytology as primary. Also, the vaccinated population may not recognise that, despite vaccination, there is a need for ongoing monitoring. With so many changes, education of the community, clinicians and women in particular is critical.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d7882e1534>Conclusions</h2><p class="" id=d7882e1537>Overall, the implementation of HPV vaccine public health programs has resulted in major decreases in vaccine-type HPV infection prevalence as well as associated disease incidence in countries that have introduced them. Administration of vaccines is ideally done prior to sexual debut for both males and females for the greatest impact. Herd and cross-protection contribute further to the impact of the vaccines. More time for observation is required to determine the effect on cancer rates, as carcinomas develop decades after infection acquisition. Although we have the tools to markedly impact HPV-related disease, we also face the challenge of ensuring that all young people, regardless of their geography, social status, or immunocompromised status, are eligible for and can access these vaccines. To observe the vaccine impact and effectiveness of national HPV vaccination programs, support is required from accurate vaccine uptake surveillance, preferably through vaccine registers in addition to genoprevalence and HPV-related disease endpoint surveillance, including cancer registries and pre-cancer screening programs.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d7882e1 class=n-a></a><h2 class=main-title id=d8135>Competing interests</h2><p class=metadata-entry><a name=d7882e121 class=n-a></a><p id=d7882e122> SG has received speaking fees from Merck Sharp &amp; Dohme (MSD) and Sanofi Pasteur MSD for work performed in her personal time. Merck paid for her travel and accommodation to present at HPV Advisory Board meetings. Lai-yang Lee declares that she has no competing interests.</p></p></div><div class=back-section><a name=d7882e1 class=n-a></a><h2 class=main-title id=d8137>Grant information</h2><p>SG has received grants to her institution from the Commonwealth Department of Health for HPV genoprevalence surveillance post-vaccination, Merck and GlaxoSmithKline to perform phase 3 clinical vaccine trials, Merck to evaluate HPV in RRP post-vaccination program, Seqirus Australia for funding of the Australian Cervical Cancer Typing Study, and the Victoria Cancer Agency for a study on monitoring and effectiveness of the Australian cervical cancer program, a translation to reduction in vaccine-related HPV infection and pre-cancerous cervical lesions study (the Vaccine Against Cervical Cancer Impact and Effectiveness study) plus a study on associations and typing of early-onset cancers in young women.</p></div><div class=back-section><a name=d7882e1544 class=n-a></a><h2 class=main-title id=d7882e1546>Acknowledgements</h2><p class="" id=d7882e1549>We would like to thank David Mesher, Kevin Pollock, Charles Lacey and Susanne Krger Kjaer for their prompt replies, insightful comments and information about their respective countries vaccine programs.</p></div><div class=back-section><a name=d7882e1553 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d8446>References</h2><div class="section ref-list"><a name=d7882e1553 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d7882e1560 class=n-a></a>Forman D, de Martel C, Lacey CJ, <i> et al.</i>: Global burden of human papillomavirus and related diseases. <i>Vaccine.</i> 2012; <b>30</b>(Suppl 5): F1223. <a target=xrefwindow id=d7882e1571 href="http://www.ncbi.nlm.nih.gov/pubmed/23199955">PubMed Abstract </a> | <a target=xrefwindow id=d7882e1574 href="http://dx.doi.org/10.1016/j.vaccine.2012.07.055">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d7882e1583 class=n-a></a>Walboomers JM, Jacobs MV, Manos MM, <i> et al.</i>: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. <i>J Pathol.</i> 1999; <b>189</b>(1): 129. <a target=xrefwindow id=d7882e1594 href="http://www.ncbi.nlm.nih.gov/pubmed/10451482">PubMed Abstract </a> | <a target="xrefwindow" id="d7882e1597" href="http://dx.doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431&gt;3.0.CO;2-F">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d7882e1606 class=n-a></a>Giuliano AR, Harris R, Sedjo RL, <i> et al.</i>: Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study. <i>J Infect Dis.</i> 2002; <b>186</b>(4): 4629. <a target=xrefwindow id=d7882e1617 href="http://www.ncbi.nlm.nih.gov/pubmed/12195372">PubMed Abstract </a> | <a target=xrefwindow id=d7882e1620 href="http://dx.doi.org/10.1086/341782">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d7882e1629 class=n-a></a>Monsonego J, Bosch FX, Coursaget P, <i> et al.</i>: Cervical cancer control, priorities and new directions. <i>Int J Cancer.</i> 2004; <b>108</b>(3): 32933. <a target=xrefwindow id=d7882e1640 href="http://www.ncbi.nlm.nih.gov/pubmed/14648697">PubMed Abstract </a> | <a target=xrefwindow id=d7882e1643 href="http://dx.doi.org/10.1002/ijc.11530">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d7882e1652 class=n-a></a>Wright TC Jr: Natural history of HPV infections. <i>J Fam Pract.</i> Quadrant Healthcom, Inc; 2009; <b>58</b>(9 Suppl HPV): S37. <a target=xrefwindow id=d7882e1660 href="http://www.ncbi.nlm.nih.gov/pubmed/19744423">PubMed Abstract </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d7882e1670 class=n-a></a>Gravitt PE: Evidence and impact of human papillomavirus latency. <i>Open Virol J.</i> 2012; <b>6</b>(Suppl 2): 198203. <a target=xrefwindow id=d7882e1678 href="http://www.ncbi.nlm.nih.gov/pubmed/23341855">PubMed Abstract </a> | <a target=xrefwindow id=d7882e1681 href="http://dx.doi.org/10.2174/1874357901206010198">Publisher Full Text </a> | <a target=xrefwindow id=d7882e1684 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3547385">Free Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d7882e1693 class=n-a></a>Hampton T: Nobel Prize honors HIV, HPV discoveries. <i>JAMA.</i> 2008; <b>300</b>(18): 2109. <a target=xrefwindow id=d7882e1701 href="http://www.ncbi.nlm.nih.gov/pubmed/19001616">PubMed Abstract </a> | <a target=xrefwindow id=d7882e1704 href="http://dx.doi.org/10.1001/jama.2008.616">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d7882e1713 class=n-a></a>Clifford GM, Smith JS, Plummer M, <i> et al.</i>: Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. <i>Br J Cancer.</i> 2003; <b>88</b>(1): 6373. <a target=xrefwindow id=d7882e1724 href="http://www.ncbi.nlm.nih.gov/pubmed/12556961">PubMed Abstract </a> | <a target=xrefwindow id=d7882e1727 href="http://dx.doi.org/10.1038/sj.bjc.6600688">Publisher Full Text </a> | <a target=xrefwindow id=d7882e1731 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2376782">Free Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d7882e1740 class=n-a></a>World Health Organisation: Media Centre: Human Papillomavirus(HPV) and cervical cancer. 2016. <a target=xrefwindow id=d7882e1742 href="http://www.who.int/mediacentre/factsheets/fs380/en/">Reference Source</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1157785"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e1751 class=n-a></a>Garland SM, Steben M, Sings HL, <i> et al.</i>: Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. <i>J Infect Dis.</i> 2009; <b>199</b>(6): 80514. <a target=xrefwindow id=d7882e1762 href="http://www.ncbi.nlm.nih.gov/pubmed/19199546">PubMed Abstract </a> | <a target=xrefwindow id=d7882e1765 href="http://dx.doi.org/10.1086/597071">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1157785">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d7882e1778 class=n-a></a>Somers GR, Tabrizi SN, Borg AJ, <i> et al.</i>: Juvenile laryngeal papillomatosis in a pediatric population: a clinicopathologic study. <i>Pediatr Pathol Lab Med.</i> 1997; <b>17</b>(1): 5364. <a target=xrefwindow id=d7882e1789 href="http://www.ncbi.nlm.nih.gov/pubmed/9050060">PubMed Abstract </a> | <a target=xrefwindow id=d7882e1792 href="http://dx.doi.org/10.1080/107710497175029">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d7882e1802 class=n-a></a>Wheeler CM, Castellsagu X, Garland SM, <i> et al.</i>: Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. <i>Lancet Oncol.</i> 2012; <b>13</b>(1): 10010. <a target=xrefwindow id=d7882e1813 href="http://www.ncbi.nlm.nih.gov/pubmed/22075170">PubMed Abstract </a> | <a target=xrefwindow id=d7882e1816 href="http://dx.doi.org/10.1016/S1470-2045(11)70287-X">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/13371977"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e1825 class=n-a></a>Lehtinen M, Paavonen J, Wheeler CM, <i> et al.</i>: Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. <i>Lancet Oncol.</i> 2012; <b>13</b>(1): 8999. <a target=xrefwindow id=d7882e1836 href="http://www.ncbi.nlm.nih.gov/pubmed/22075171">PubMed Abstract </a> | <a target=xrefwindow id=d7882e1839 href="http://dx.doi.org/10.1016/S1470-2045(11)70286-8">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/13371977">F1000 Recommendation</a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1088787"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e1852 class=n-a></a>Garland SM, Hernandez-Avila M, Wheeler CM, <i> et al.</i>: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. <i>N Engl J Med.</i> 2007; <b>356</b>(19): 192843. <a target=xrefwindow id=d7882e1863 href="http://www.ncbi.nlm.nih.gov/pubmed/17494926">PubMed Abstract </a> | <a target=xrefwindow id=d7882e1866 href="http://dx.doi.org/10.1056/NEJMoa061760">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1088787">F1000 Recommendation</a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1088288"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e1879 class=n-a></a>FUTURE II Study Group: Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. <i>N Engl J Med.</i> 2007; <b>356</b>(19): 191527. <a target=xrefwindow id=d7882e1887 href="http://www.ncbi.nlm.nih.gov/pubmed/17494925">PubMed Abstract </a> | <a target=xrefwindow id=d7882e1890 href="http://dx.doi.org/10.1056/NEJMoa061741">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1088288">F1000 Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d7882e1903 class=n-a></a>Joura EA, Giuliano AR, Iversen OE, <i> et al.</i>: A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. <i>N Engl J Med.</i> 2015; <b>372</b>(8): 71123. <a target=xrefwindow id=d7882e1914 href="http://www.ncbi.nlm.nih.gov/pubmed/25693011">PubMed Abstract </a> | <a target=xrefwindow id=d7882e1917 href="http://dx.doi.org/10.1056/NEJMoa1405044">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727619883"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e1926 class=n-a></a>Brisson M, Bnard , Drolet M, <i> et al.</i>: Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: A systematic review and meta-analysis of predictions from transmission-dynamic models. <i>Lancet Public Health.</i> 2016; <b>1</b>(1): e8e17. <a target=xrefwindow id=d7882e1937 href="http://dx.doi.org/10.1016/S2468-2667(16)30001-9">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727619883">F1000 Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725380979"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e1951 class=n-a></a>Drolet M, Bnard E, Boily MC, <i> et al.</i>: Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. <i>Lancet Infect Dis.</i> 2015; <b>15</b>(5): 56580. <a target=xrefwindow id=d7882e1962 href="http://www.ncbi.nlm.nih.gov/pubmed/25744474">PubMed Abstract </a> | <a target=xrefwindow id=d7882e1965 href="http://dx.doi.org/10.1016/S1473-3099(14)71073-4">Publisher Full Text </a> | <a target=xrefwindow id=d7882e1969 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5144106">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725380979">F1000 Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727619884"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e1982 class=n-a></a>Poljak M, Kocjan BJ, Otrbenk A, <i> et al.</i>: Commercially available molecular tests for human papillomaviruses (HPV): 2015 update. <i>J Clin Virol.</i> 2016; <b>76</b>(Suppl 1): S3S13. <a target=xrefwindow id=d7882e1993 href="http://www.ncbi.nlm.nih.gov/pubmed/26601820">PubMed Abstract </a> | <a target=xrefwindow id=d7882e1996 href="http://dx.doi.org/10.1016/j.jcv.2015.10.023">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727619884">F1000 Recommendation</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d7882e2009 class=n-a></a>Snijders PJ, van den Brule AJ, Meijer CJ: The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. <i>J Pathol.</i> 2003; <b>201</b>(1): 16. <a target=xrefwindow id=d7882e2017 href="http://www.ncbi.nlm.nih.gov/pubmed/12950011">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2020 href="http://dx.doi.org/10.1002/path.1433">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d7882e2029 class=n-a></a>Pagliusi SR, Garland SM: International standard reagents for HPV detection. <i>Dis Markers.</i> 2007; <b>23</b>(4): 28396. <a target=xrefwindow id=d7882e2037 href="http://www.ncbi.nlm.nih.gov/pubmed/17627063">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2040 href="http://dx.doi.org/10.1155/2007/591826">Publisher Full Text </a> | <a target=xrefwindow id=d7882e2043 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3851336">Free Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d7882e2052 class=n-a></a>Garland SM, Kjaer SK, Muoz N, <i> et al.</i>: Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. <i>Clin Infect Dis.</i> 2016; <b>63</b>(4): 51927. <a target=xrefwindow id=d7882e2063 href="http://www.ncbi.nlm.nih.gov/pubmed/27230391">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2066 href="http://dx.doi.org/10.1093/cid/ciw354">Publisher Full Text </a> | <a target=xrefwindow id=d7882e2070 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4967609">Free Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d7882e2079 class=n-a></a>Garland SM, Skinner SR, Brotherton JM: Adolescent and young adult HPV vaccination in Australia: achievements and challenges. <i>Prev Med.</i> 2011; <b>53</b>(Suppl 1): S2935. <a target=xrefwindow id=d7882e2087 href="http://www.ncbi.nlm.nih.gov/pubmed/21962468">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2090 href="http://dx.doi.org/10.1016/j.ypmed.2011.08.015">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d7882e2100 class=n-a></a>Garland SM, Molesworth EG, Machalek DA, <i> et al.</i>: How to best measure the effectiveness of male human papillomavirus vaccine programmes? <i>Clin Microbiol Infect.</i> 2015; <b>21</b>(9): 83441. <a target=xrefwindow id=d7882e2111 href="http://www.ncbi.nlm.nih.gov/pubmed/26055415">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2114 href="http://dx.doi.org/10.1016/j.cmi.2015.05.038">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d7882e2123 class=n-a></a>National HPV Vaccination Program Register: HPV vaccination coverage by dose number (Australia) for males by age group in mid 2014. [cited 2017 Jan 8]. <a target=xrefwindow id=d7882e2125 href="http://www.hpvregister.org.au/site/DefaultSite/filesystem/documents/Coverage-Data/2015/Coverage%20by%20dose%202014%20-%20males.pdf">Reference Source</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718202042"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e2134 class=n-a></a>Brotherton JM, Liu B, Donovan B, <i> et al.</i>: Human papillomavirus (HPV) vaccination coverage in young Australian women is higher than previously estimated: independent estimates from a nationally representative mobile phone survey. <i>Vaccine.</i> 2014; <b>32</b>(5): 5927. <a target=xrefwindow id=d7882e2145 href="http://www.ncbi.nlm.nih.gov/pubmed/24316239">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2148 href="http://dx.doi.org/10.1016/j.vaccine.2013.11.075">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718202042">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717968139"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e2161 class=n-a></a>Tabrizi SN, Brotherton JM, Kaldor JM, <i> et al.</i>: Fall in human papillomavirus prevalence following a national vaccination program. <i>J Infect Dis.</i> 2012; <b>206</b>(11): 164551. <a target=xrefwindow id=d7882e2172 href="http://www.ncbi.nlm.nih.gov/pubmed/23087430">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2175 href="http://dx.doi.org/10.1093/infdis/jis590">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717968139">F1000 Recommendation</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d7882e2188 class=n-a></a>Tabrizi SN, Brotherton JM, Kaldor JM, <i> et al.</i>: Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. <i>Lancet Infect Dis.</i> 2014; <b>14</b>(10): 95866. <a target=xrefwindow id=d7882e2199 href="http://www.ncbi.nlm.nih.gov/pubmed/25107680">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2202 href="http://dx.doi.org/10.1016/S1473-3099(14)70841-2">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d7882e2211 class=n-a></a>Machalek DA, Chow EP, Garland SM, <i> et al.</i>: Human Papillomavirus Prevalence in Unvaccinated Heterosexual Men After a National Female Vaccination Program. <i>J Infect Dis.</i> 2017; <b>215</b>(2): 2028. <a target=xrefwindow id=d7882e2222 href="http://www.ncbi.nlm.nih.gov/pubmed/27815379">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2225 href="http://dx.doi.org/10.1093/infdis/jiw530">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718353550"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e2235 class=n-a></a>Kavanagh K, Pollock KG, Potts A, <i> et al.</i>: Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. <i>Br J Cancer.</i> 2014; <b>110</b>(11): 280411. <a target=xrefwindow id=d7882e2246 href="http://www.ncbi.nlm.nih.gov/pubmed/24736582">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2249 href="http://dx.doi.org/10.1038/bjc.2014.198">Publisher Full Text </a> | <a target=xrefwindow id=d7882e2253 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4037824">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718353550">F1000 Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718021324"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e2266 class=n-a></a>Markowitz LE, Hariri S, Lin C, <i> et al.</i>: Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 20032010. <i>J Infect Dis.</i> 2013; <b>208</b>(3): 38593. <a target=xrefwindow id=d7882e2277 href="http://www.ncbi.nlm.nih.gov/pubmed/23785124">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2280 href="http://dx.doi.org/10.1093/infdis/jit192">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718021324">F1000 Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726172739"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e2293 class=n-a></a>Markowitz LE, Liu G, Hariri S, <i> et al.</i>: Prevalence of HPV After Introduction of the Vaccination Program in the United States. <i>Pediatrics.</i> 2016; <b>137</b>(3): e20151968. <a target=xrefwindow id=d7882e2304 href="http://www.ncbi.nlm.nih.gov/pubmed/26908697">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2307 href="http://dx.doi.org/10.1542/peds.2015-1968">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726172739">F1000 Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726942954"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e2320 class=n-a></a>Berenson AB, Laz TH, Rahman M: Reduction in Vaccine-Type Human Papillomavirus Prevalence Among Women in the United States, 20092012. <i>J Infect Dis.</i> 2016; <b>214</b>(12): 19614. <a target=xrefwindow id=d7882e2328 href="http://www.ncbi.nlm.nih.gov/pubmed/27821406">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2331 href="http://dx.doi.org/10.1093/infdis/jiw515">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726942954">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d7882e2344 class=n-a></a>Kjaer SK, Tran TN, Sparen P, <i> et al.</i>: The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. <i>J Infect Dis.</i> 2007; <b>196</b>(10): 144754. <a target=xrefwindow id=d7882e2355 href="http://www.ncbi.nlm.nih.gov/pubmed/18008222">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2358 href="http://dx.doi.org/10.1086/522863">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/8980956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e2367 class=n-a></a>Donovan B, Franklin N, Guy R, <i> et al.</i>: Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. <i>Lancet Infect Dis.</i> 2011; <b>11</b>(1): 3944. <a target=xrefwindow id=d7882e2378 href="http://www.ncbi.nlm.nih.gov/pubmed/21067976">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2381 href="http://dx.doi.org/10.1016/S1473-3099(10)70225-5">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/8980956">F1000 Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/13416963"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e2395 class=n-a></a>Read TR, Hocking JS, Chen MY, <i> et al.</i>: The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. <i>Sex Transm Infect.</i> 2011; <b>87</b>(7): 5447. <a target=xrefwindow id=d7882e2406 href="http://www.ncbi.nlm.nih.gov/pubmed/21970896">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2409 href="http://dx.doi.org/10.1136/sextrans-2011-050234">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/13416963">F1000 Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718009332"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e2422 class=n-a></a>Ali H, Donovan B, Wand H, <i> et al.</i>: Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. <i>BMJ.</i> 2013; <b>346</b>: f2032. <a target=xrefwindow id=d7882e2433 href="http://www.ncbi.nlm.nih.gov/pubmed/23599298">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2436 href="http://dx.doi.org/10.1136/bmj.f2032">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718009332">F1000 Recommendation</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d7882e2449 class=n-a></a>Howell-Jones R, Soldan K, Wetten S, <i> et al.</i>: Declining genital Warts in young women in england associated with HPV 16/18 vaccination: an ecological study. <i>J Infect Dis.</i> 2013; <b>208</b>(9): 1397403. <a target=xrefwindow id=d7882e2460 href="http://www.ncbi.nlm.nih.gov/pubmed/24092908">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2463 href="http://dx.doi.org/10.1093/infdis/jit361">Publisher Full Text </a> | <a target=xrefwindow id=d7882e2467 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3789575">Free Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d7882e2476 class=n-a></a>Szarewski A, Skinner SR, Garland SM, <i> et al.</i>: Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation. <i>J Infect Dis.</i> 2013; <b>208</b>(9): 13916. <a target=xrefwindow id=d7882e2487 href="http://www.ncbi.nlm.nih.gov/pubmed/24092907">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2490 href="http://dx.doi.org/10.1093/infdis/jit360">Publisher Full Text </a> | <a target=xrefwindow id=d7882e2494 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3789574">Free Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718316024"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e2503 class=n-a></a>Dochez C, Bogers JJ, Verhelst R, <i> et al.</i>: HPV vaccines to prevent cervical cancer and genital warts: an update. <i>Vaccine.</i> 2014; <b>32</b>(14): 1595601. <a target=xrefwindow id=d7882e2514 href="http://www.ncbi.nlm.nih.gov/pubmed/24606637">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2517 href="http://dx.doi.org/10.1016/j.vaccine.2013.10.081">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718316024">F1000 Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d7882e2530 class=n-a></a>Baandrup L, Blomberg M, Dehlendorff C, <i> et al.</i>: Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. <i>Sex Transm Dis.</i> 2013; <b>40</b>(2): 1305. <a target=xrefwindow id=d7882e2541 href="http://www.ncbi.nlm.nih.gov/pubmed/23324976">PubMed Abstract </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726257062"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e2551 class=n-a></a>Bollerup S, Baldur-Felskov B, Blomberg M, <i> et al.</i>: Significant Reduction in the Incidence of Genital Warts in Young Men 5 Years into the Danish Human Papillomavirus Vaccination Program for Girls and Women. <i>Sex Transm Dis.</i> 2016; <b>43</b>(4): 23842. <a target=xrefwindow id=d7882e2562 href="http://www.ncbi.nlm.nih.gov/pubmed/26967300">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2565 href="http://dx.doi.org/10.1097/OLQ.0000000000000418">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726257062">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d7882e2578 class=n-a></a>Blomberg M, Dehlendorff C, Munk C, <i> et al.</i>: Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark. <i>Clin Infect Dis.</i> 2013; <b>57</b>(7): 92934. <a target=xrefwindow id=d7882e2589 href="http://www.ncbi.nlm.nih.gov/pubmed/23804192">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2592 href="http://dx.doi.org/10.1093/cid/cit436">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727573575"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e2601 class=n-a></a>Dominiak-Felden G, Gobbo C, Simondon F: Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study. <i>PLoS One.</i> 2015; <b>10</b>(7): e0132404. <a target=xrefwindow id=d7882e2609 href="http://www.ncbi.nlm.nih.gov/pubmed/26147096">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2612 href="http://dx.doi.org/10.1371/journal.pone.0132404">Publisher Full Text </a> | <a target=xrefwindow id=d7882e2615 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4492693">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727573575">F1000 Recommendation</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d7882e2628 class=n-a></a>Australian Government. Australian Insititue of Health and Welfare: Cervical screening in Australia 20132014. [cited 2017 Jan 8]. <a target=xrefwindow id=d7882e2630 href="http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=60129554884">Reference Source</a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d7882e2639 class=n-a></a>Brotherton JM, Fridman M, May CL, <i> et al.</i>: Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. <i>Lancet.</i> 2011; <b>377</b>(9783): 208592. <a target=xrefwindow id=d7882e2650 href="http://www.ncbi.nlm.nih.gov/pubmed/21684381">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2653 href="http://dx.doi.org/10.1016/S0140-6736(11)60551-5">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d7882e2662 class=n-a></a>Gertig DM, Brotherton JM, Budd AC, <i> et al.</i>: Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. <i>BMC Med.</i> 2013; <b>11</b>: 227. <a target=xrefwindow id=d7882e2673 href="http://www.ncbi.nlm.nih.gov/pubmed/24148310">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2676 href="http://dx.doi.org/10.1186/1741-7015-11-227">Publisher Full Text </a> | <a target=xrefwindow id=d7882e2680 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4015688">Free Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d7882e2690 class=n-a></a>Brotherton JM, Saville AM, May CL, <i> et al.</i>: Human papillomavirus vaccination is changing the epidemiology of high-grade cervical lesions in Australia. <i>Cancer Causes Control.</i> 2015; <b>26</b>(6): 9534. <a target=xrefwindow id=d7882e2701 href="http://www.ncbi.nlm.nih.gov/pubmed/25804857">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2704 href="http://dx.doi.org/10.1007/s10552-015-0568-6">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718553853"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e2713 class=n-a></a>Pollock KG, Kavanagh K, Potts A, <i> et al.</i>: Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. <i>Br J Cancer.</i> 2014; <b>111</b>(9): 182430. <a target=xrefwindow id=d7882e2724 href="http://www.ncbi.nlm.nih.gov/pubmed/25180766">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2727 href="http://dx.doi.org/10.1038/bjc.2014.479">Publisher Full Text </a> | <a target=xrefwindow id=d7882e2731 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4453734">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718553853">F1000 Recommendation</a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718283250"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e2744 class=n-a></a>Baldur-Felskov B, Dehlendorff C, Munk C, <i> et al.</i>: Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow-up of young Danish women. <i>J Natl Cancer Inst.</i> 2014; <b>106</b>(3): djt460. <a target=xrefwindow id=d7882e2755 href="http://www.ncbi.nlm.nih.gov/pubmed/24552678">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2758 href="http://dx.doi.org/10.1093/jnci/djt460">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718283250">F1000 Recommendation</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718377293"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e2771 class=n-a></a>Baldur-Felskov B, Dehlendorff C, Junge J, <i> et al.</i>: Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program. <i>Cancer Causes Control.</i> 2014; <b>25</b>(7): 91522. <a target=xrefwindow id=d7882e2782 href="http://www.ncbi.nlm.nih.gov/pubmed/24797870">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2785 href="http://dx.doi.org/10.1007/s10552-014-0392-4">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718377293">F1000 Recommendation</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727619888"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e2798 class=n-a></a>Baldur-Felskov B, Munk C, Nielsen TS, <i> et al.</i>: Trends in the incidence of cervical cancer and severe precancerous lesions in Denmark, 19972012. <i>Cancer Causes Control.</i> 2015; <b>26</b>(8): 110516. <a target=xrefwindow id=d7882e2809 href="http://www.ncbi.nlm.nih.gov/pubmed/26033777">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2812 href="http://dx.doi.org/10.1007/s10552-015-0603-7">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727619888">F1000 Recommendation</a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726169324"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e2825 class=n-a></a>Skinner SR, Apter D, De Carvalho N, <i> et al.</i>: Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases. <i>Expert Rev Vaccines.</i> 2016; <b>15</b>(3): 36787. <a target=xrefwindow id=d7882e2836 href="http://www.ncbi.nlm.nih.gov/pubmed/26902666">PubMed Abstract </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726169324">F1000 Recommendation</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d7882e2850 class=n-a></a>Australian Government Cancer Australia: Cervical cancer in Australia. [cited 2017 Jan 8]. <a target=xrefwindow id=d7882e2852 href="https://cervical-cancer.canceraustralia.gov.au/statistics">Reference Source</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d7882e2861 class=n-a></a>Cancer Research UK: Cervical cancer incidence statistics. [cited 2017 Mar 21]. <a target=xrefwindow id=d7882e2863 href="http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/cervical-cancer/incidence#heading-One">Reference Source</a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718195125"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e2872 class=n-a></a>van Kriekinge G, Castellsague X, Cibula D, <i> et al.</i>: Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths. <i>Vaccine.</i> 2014; <b>32</b>(6): 7339. <a target=xrefwindow id=d7882e2883 href="http://www.ncbi.nlm.nih.gov/pubmed/24291200">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2886 href="http://dx.doi.org/10.1016/j.vaccine.2013.11.049">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718195125">F1000 Recommendation</a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725583719"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e2899 class=n-a></a>Riethmuller D, Jacquard A, Lacau St Guily J, <i> et al.</i>: Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France. <i>BMC Public Health.</i> 2015; <b>15</b>: 453. <a target=xrefwindow id=d7882e2910 href="http://www.ncbi.nlm.nih.gov/pubmed/25934423">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2913 href="http://dx.doi.org/10.1186/s12889-015-1779-1">Publisher Full Text </a> | <a target=xrefwindow id=d7882e2917 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4433025">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725583719">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725953428"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e2930 class=n-a></a>Luckett R, Feldman S: Impact of 2-, 4- and 9-valent HPV vaccines on morbidity and mortality from cervical cancer. <i>Hum Vaccin Immunother.</i> 2016; <b>12</b>(6): 133242. <a target=xrefwindow id=d7882e2938 href="http://www.ncbi.nlm.nih.gov/pubmed/26588179">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2941 href="http://dx.doi.org/10.1080/21645515.2015.1108500">Publisher Full Text </a> | <a target=xrefwindow id=d7882e2944 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4964711">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725953428">F1000 Recommendation</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727619891"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e2957 class=n-a></a>Buchanan TR, Graybill WS, Pierce JY: Morbidity and mortality of vulvar and vaginal cancers: Impact of 2-, 4-, and 9-valent HPV vaccines. <i>Hum Vaccin Immunother.</i> 2016; <b>12</b>(6): 13526. <a target=xrefwindow id=d7882e2965 href="http://www.ncbi.nlm.nih.gov/pubmed/26901390">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2968 href="http://dx.doi.org/10.1080/21645515.2016.1147634">Publisher Full Text </a> | <a target=xrefwindow id=d7882e2971 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4964646">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727619891">F1000 Recommendation</a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727619892"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e2985 class=n-a></a>Stier EA, Chigurupati NL, Fung L: Prophylactic HPV vaccination and anal cancer. <i>Hum Vaccin Immunother.</i> 2016; <b>12</b>(6): 134851. <a target=xrefwindow id=d7882e2993 href="http://www.ncbi.nlm.nih.gov/pubmed/26933898">PubMed Abstract </a> | <a target=xrefwindow id=d7882e2996 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4964669">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727619892">F1000 Recommendation</a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d7882e3009 class=n-a></a>National HPV Vaccination Program Register: HPV Vaccination Coverage. [cited 2017 Jan 13]. <a target=xrefwindow id=d7882e3011 href="http://www.hpvregister.org.au/research/coverage-data/HPV-vaccination-coverage-by-dose-2015">Reference Source</a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d7882e3020 class=n-a></a>Garland SM: The Australian experience with the human papillomavirus vaccine. <i>Clin Ther.</i> 2014; <b>36</b>(1): 1723. <a target=xrefwindow id=d7882e3028 href="http://www.ncbi.nlm.nih.gov/pubmed/24417782">PubMed Abstract </a> | <a target=xrefwindow id=d7882e3031 href="http://dx.doi.org/10.1016/j.clinthera.2013.12.005">Publisher Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d7882e3040 class=n-a></a>Oliver K, Frawley A, Garland E: HPV vaccination: Population approaches for improving rates. <i>Hum Vaccin Immunother.</i> 2016; <b>12</b>(6): 158993. <a target=xrefwindow id=d7882e3048 href="http://www.ncbi.nlm.nih.gov/pubmed/26890685">PubMed Abstract </a> | <a target=xrefwindow id=d7882e3051 href="http://dx.doi.org/10.1080/21645515.2016.1139253">Publisher Full Text </a> | <a target=xrefwindow id=d7882e3054 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4964670">Free Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726257863"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e3063 class=n-a></a>Gee J, Weinbaum C, Sukumaran L, <i> et al.</i>: Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States. <i>Hum Vaccin Immunother.</i> 2016; <b>12</b>(6): 140617. <a target=xrefwindow id=d7882e3074 href="http://www.ncbi.nlm.nih.gov/pubmed/27029786">PubMed Abstract </a> | <a target=xrefwindow id=d7882e3077 href="http://dx.doi.org/10.1080/21645515.2016.1168952">Publisher Full Text </a> | <a target=xrefwindow id=d7882e3081 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4964727">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726257863">F1000 Recommendation</a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725251333"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e3094 class=n-a></a>Naud PS, Roteli-Martins CM, Carvalho NS, <i> et al.</i>: Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. <i>Hum Vaccin Immunother.</i> 2014; <b>10</b>(8): 214762. <a target=xrefwindow id=d7882e3105 href="http://www.ncbi.nlm.nih.gov/pubmed/25424918">PubMed Abstract </a> | <a target=xrefwindow id=d7882e3108 href="http://dx.doi.org/10.4161/hv.29532">Publisher Full Text </a> | <a target=xrefwindow id=d7882e3112 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4896780">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725251333">F1000 Recommendation</a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d7882e3126 class=n-a></a>Garland SM, Stanley M, Brotheron J, <i> et al.</i>: IPVS Policy statement on safety of HPV vaccines. <i>Papillomavirus Res.</i> 2016; <b>2</b>: 910. <a target=xrefwindow id=d7882e3137 href="http://dx.doi.org/10.1016/j.pvr.2015.11.001">Publisher Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d7882e3146 class=n-a></a>Centers for Disease Control and Prevention: Frequently asked Questions about HPV Vaccine Safety. [cited 2017 Mar 13]. <a target=xrefwindow id=d7882e3148 href="https://www.cdc.gov/vaccinesafety/vaccines/hpv/hpv-safety-faqs.html">Reference Source</a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d7882e3157 class=n-a></a>Larson HJ, Wilson R, Hanley S, <i> et al.</i>: Tracking the global spread of vaccine sentiments: the global response to Japan's suspension of its HPV vaccine recommendation. <i>Hum Vaccin Immunother.</i> 2014; <b>10</b>(9): 254350. <a target=xrefwindow id=d7882e3168 href="http://www.ncbi.nlm.nih.gov/pubmed/25483472">PubMed Abstract </a> | <a target=xrefwindow id=d7882e3171 href="http://dx.doi.org/10.4161/21645515.2014.969618">Publisher Full Text </a> | <a target=xrefwindow id=d7882e3175 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4977439">Free Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d7882e3184 class=n-a></a>Tanaka Y, Ueda Y, Egawa-Takata T, <i> et al.</i>: Outcomes for girls without HPV vaccination in Japan. <i>Lancet Oncol.</i> 2016; <b>17</b>(7): 8689. <a target=xrefwindow id=d7882e3195 href="http://www.ncbi.nlm.nih.gov/pubmed/27396634">PubMed Abstract </a> | <a target=xrefwindow id=d7882e3198 href="http://dx.doi.org/10.1016/S1470-2045(16)00147-9">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d7882e3207 class=n-a></a>Hanley SJ, Yoshioka E, Ito Y, <i> et al.</i>: HPV vaccination crisis in Japan. <i>Lancet.</i> 2015; <b>385</b>(9987): 2571. <a target=xrefwindow id=d7882e3218 href="http://www.ncbi.nlm.nih.gov/pubmed/26122153">PubMed Abstract </a> | <a target=xrefwindow id=d7882e3221 href="http://dx.doi.org/10.1016/S0140-6736(15)61152-7">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d7882e3230 class=n-a></a>Vichnin M, Bonanni P, Klein NP, <i> et al.</i>: An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015. <i>Pediatr Infect Dis J.</i> 2015; <b>34</b>(9): 98391. <a target=xrefwindow id=d7882e3241 href="http://www.ncbi.nlm.nih.gov/pubmed/26107345">PubMed Abstract </a> | <a target=xrefwindow id=d7882e3244 href="http://dx.doi.org/10.1097/INF.0000000000000793">Publisher Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d7882e3254 class=n-a></a>Safety of HPV Vaccines: Global Vaccine Safety. [Internet]. [cited 2017 Jan 8]. <a target=xrefwindow id=d7882e3256 href="http://www.who.int/vaccine_safety/committee/topics/hpv/Dec_2015/en">Reference Source</a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d7882e3265 class=n-a></a>World Health Organisation: Immunisation, Vaccines and Biologicals: Human Papillomavirus (HPV). 2016, [cited 2017 Jan 3]. <a target=xrefwindow id=d7882e3267 href="http://www.who.int/immunization/diseases/hpv/en/">Reference Source</a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d7882e3276 class=n-a></a>Centers for Disease Control and Prevention: Human Papillomavirus (HPV) Vaccine Safety. [cited 2017 Jan 14]. <a target=xrefwindow id=d7882e3278 href="https://www.cdc.gov/vaccinesafety/vaccines/hpv-vaccine.html">Reference Source</a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1123910"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e3287 class=n-a></a>Stanley M: Immune responses to human papillomavirus. <i>Vaccine.</i> 2006; <b>24</b>(Suppl 1): S1622. <a target=xrefwindow id=d7882e3295 href="http://www.ncbi.nlm.nih.gov/pubmed/16219398">PubMed Abstract </a> | <a target=xrefwindow id=d7882e3298 href="http://dx.doi.org/10.1016/j.vaccine.2005.09.002">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1123910">F1000 Recommendation</a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d7882e3311 class=n-a></a>Basu P, Bhatla N, Ngoma T, <i> et al.</i>: Less than 3 doses of the HPV vaccine-Review of efficacy against virological and disease end points. <i>Hum Vaccin Immunother.</i> 2016; <b>12</b>(6): 1394402. <a target=xrefwindow id=d7882e3322 href="http://www.ncbi.nlm.nih.gov/pubmed/26933961">PubMed Abstract </a> | <a target=xrefwindow id=d7882e3325 href="http://dx.doi.org/10.1080/21645515.2016.1146429">Publisher Full Text </a> | <a target=xrefwindow id=d7882e3329 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4964672">Free Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d7882e3338 class=n-a></a>Australian Technical Advisory Group on Immunisation (ATAGI): The Australian Immunisation Handbook 10th ed (2016 update). Canberra: Australian Government Department of Health. 2016. <a target=xrefwindow id=d7882e3340 href="http://www.phcris.org.au/resources/item.php?id=8948&amp;spindex=18">Reference Source</a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d7882e3350 class=n-a></a>Smith MA, Lew JB, Walker RJ, <i> et al.</i>: The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. <i>Vaccine.</i> 2011; <b>29</b>(48): 911222. <a target=xrefwindow id=d7882e3361 href="http://www.ncbi.nlm.nih.gov/pubmed/21419773">PubMed Abstract </a> | <a target=xrefwindow id=d7882e3364 href="http://dx.doi.org/10.1016/j.vaccine.2011.02.091">Publisher Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718518955"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e3373 class=n-a></a>Smith MA, Canfell K: Incremental benefits of male HPV vaccination: accounting for inequality in population uptake. <i>PLoS One.</i> 2014; <b>9</b>(8): e101048. <a target=xrefwindow id=d7882e3381 href="http://www.ncbi.nlm.nih.gov/pubmed/25089637">PubMed Abstract </a> | <a target=xrefwindow id=d7882e3384 href="http://dx.doi.org/10.1371/journal.pone.0101048">Publisher Full Text </a> | <a target=xrefwindow id=d7882e3387 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4121069">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718518955">F1000 Recommendation</a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727619894"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e3400 class=n-a></a>Largeron N, Petry KU, Jacob J, <i> et al.</i>: An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany. <i>Expert Rev Pharmacoecon Outcomes Res.</i> 2017; <b>17</b>(1): 8598. <a target=xrefwindow id=d7882e3411 href="http://www.ncbi.nlm.nih.gov/pubmed/27366939">PubMed Abstract </a> | <a target=xrefwindow id=d7882e3414 href="http://dx.doi.org/10.1080/14737167.2016.1208087">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727619894">F1000 Recommendation</a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718159737"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e3427 class=n-a></a>Drolet M, Laprise JF, Boily MC, <i> et al.</i>: Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine. <i>Int J Cancer.</i> 2014; <b>134</b>(9): 22648. <a target=xrefwindow id=d7882e3438 href="http://www.ncbi.nlm.nih.gov/pubmed/24174175">PubMed Abstract </a> | <a target=xrefwindow id=d7882e3441 href="http://dx.doi.org/10.1002/ijc.28541">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718159737">F1000 Recommendation</a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d7882e3454 class=n-a></a>Skinner SR, Szarewski A, Romanowski B, <i> et al.</i>: Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. <i>Lancet.</i> 2014; <b>384</b>(9961): 221327. <a target=xrefwindow id=d7882e3465 href="http://www.ncbi.nlm.nih.gov/pubmed/25189358">PubMed Abstract </a> | <a target=xrefwindow id=d7882e3468 href="http://dx.doi.org/10.1016/S0140-6736(14)60920-X">Publisher Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d7882e3477 class=n-a></a>Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, <i> et al.</i>: Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. <i>Lancet Infect Dis.</i> 2016; <b>16</b>(10): 115468. <a target=xrefwindow id=d7882e3488 href="http://www.ncbi.nlm.nih.gov/pubmed/27373900">PubMed Abstract </a> | <a target=xrefwindow id=d7882e3491 href="http://dx.doi.org/10.1016/S1473-3099(16)30120-7">Publisher Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1161602"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d7882e3501 class=n-a></a>Munoz N, Manalastas R Jr, Pitisuttithum P, <i> et al.</i>: Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 2445 years: a randomised, double-blind trial. <i>Lancet.</i> 2009; <b>373</b>(9679): 194957. <a target=xrefwindow id=d7882e3512 href="http://www.ncbi.nlm.nih.gov/pubmed/19493565">PubMed Abstract </a> | <a target=xrefwindow id=d7882e3515 href="http://dx.doi.org/10.1016/S0140-6736(09)60691-7">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1161602">F1000 Recommendation</a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d7882e3528 class=n-a></a>Haupt RM, Wheeler CM, Brown DR, <i> et al.</i>: Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection. <i>Int J Cancer.</i> 2011; <b>129</b>(11): 263242. <a target=xrefwindow id=d7882e3539 href="http://www.ncbi.nlm.nih.gov/pubmed/21491420">PubMed Abstract </a> | <a target=xrefwindow id=d7882e3542 href="http://dx.doi.org/10.1002/ijc.25940">Publisher Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d7882e3551 class=n-a></a>Olsson SE, Kjaer SK, Sigurdsson K, <i> et al.</i>: Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. <i>Hum Vaccin.</i> 2009; <b>5</b>(10): 696704. <a target=xrefwindow id=d7882e3562 href="http://www.ncbi.nlm.nih.gov/pubmed/19855170">PubMed Abstract </a> | <a target=xrefwindow id=d7882e3565 href="http://dx.doi.org/10.4161/hv.5.10.9515">Publisher Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d7882e3574 class=n-a></a>Szarewski A, Poppe WA, Skinner SR, <i> et al.</i>: Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 1525 years with and without serological evidence of previous exposure to HPV-16/18. <i>Int J Cancer.</i> 2012; <b>131</b>(1): 10616. <a target=xrefwindow id=d7882e3585 href="http://www.ncbi.nlm.nih.gov/pubmed/21858807">PubMed Abstract </a> | <a target=xrefwindow id=d7882e3588 href="http://dx.doi.org/10.1002/ijc.26362">Publisher Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d7882e3597 class=n-a></a>Bosch FX, Robles C, Daz M, <i> et al.</i>: HPV-FASTER: broadening the scope for prevention of HPV-related cancer. <i>Nat Rev Clin Oncol.</i> 2016; <b>13</b>(2): 11932. <a target=xrefwindow id=d7882e3608 href="http://www.ncbi.nlm.nih.gov/pubmed/26323382">PubMed Abstract </a> | <a target=xrefwindow id=d7882e3611 href="http://dx.doi.org/10.1038/nrclinonc.2015.146">Publisher Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d7882e3620 class=n-a></a>Brotherton JM, Kaldor JM, Garland SM: Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: towards a national HPV surveillance strategy. <i>Sex Health.</i> 2010; <b>7</b>(3): 3109. <a target=xrefwindow id=d7882e3628 href="http://www.ncbi.nlm.nih.gov/pubmed/20719220">PubMed Abstract </a> | <a target=xrefwindow id=d7882e3631 href="http://dx.doi.org/10.1071/SH09137">Publisher Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d7882e3641 class=n-a></a>Stubbs R: Public Health England Screening-HPV primary screening in the cervical screening programme. [cited 2017 Mar 13]. <a target=xrefwindow id=d7882e3643 href="https://phescreening.blog.gov.uk/2016/04/13/hpv-primary-screening-in-the-cervical-screening-programme/">Reference Source</a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d7882e3652 class=n-a></a>ICO Information Centre on HPV and Cancer. hpvcentre.net. [cited 2017 Jan 13]. <a target=xrefwindow id=d7882e3654 href="http://www.hpvcentre.net">Reference Source</a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d7882e3663 class=n-a></a>Centers for Disease Control and Prevention: Human Papillomavirus (HPV). [cited 2017 Jan 8]. <a target=xrefwindow id=d7882e3665 href="https://www.cdc.gov/hpv/">Reference Source</a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d7882e3674 class=n-a></a>Centers for Disease Control and Prevention: Human Papillomavirus(HPV)ACIP Vaccine Recommendations. [cited 2017 Jan 13]. <a target=xrefwindow id=d7882e3676 href="https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hpv.html">Reference Source</a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d7882e3685 class=n-a></a>National, Regional State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17years-United States 2015 MMWR Aug 26 2016. [cited 2017 Jan 13]. <a target=xrefwindow id=d7882e3687 href="https://www.cdc.gov/mmwr/volumes/65/wr/mm6533a4.htm?s_cid=mm6533a4_w">Reference Source</a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d7882e3696 class=n-a></a>NIH National Cancer Institute: Human Papillomavirus (HPV) Vaccine.2016, [cited 2017 Jan 13]. <a target=xrefwindow id=d7882e3698 href="https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-vaccine-fact-sheet#r21">Reference Source</a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d7882e3708 class=n-a></a>Powell SE, Hariri S, Steinau M, <i> et al.</i>: Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. <i>Vaccine.</i> 2012; <b>31</b>(1): 10913. <a target=xrefwindow id=d7882e3719 href="http://www.ncbi.nlm.nih.gov/pubmed/23137842">PubMed Abstract </a> | <a target=xrefwindow id=d7882e3722 href="http://dx.doi.org/10.1016/j.vaccine.2012.10.092">Publisher Full Text </a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d7882e3731 class=n-a></a>NHS: HPV Vaccine. 2014, [cited 2017 Jan 13]. <a target=xrefwindow id=d7882e3733 href="http://www.nhs.uk/conditions/vaccinations/pages/hpv-human-papillomavirus-vaccine.aspx">Reference Source</a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a name=d7882e3742 class=n-a></a>NHS: Cervical screening. 2015, [cited 2017 Jan 13]. <a target=xrefwindow id=d7882e3744 href="http://www.nhs.uk/Conditions/Cervical-screening-test/Pages/Introduction.aspx">Reference Source</a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d7882e3753 class=n-a></a>Public Health England: Human Papillomavirus (HPV) Vaccine Coverage in England, 2008/09 to 2013/14, A review of the full six years of the three-dose schedule. 2015, [cited 2017 Jan 13]. <a target=xrefwindow id=d7882e3755 href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/412264/HPV_Vaccine_Coverage_in_England_200809_to_201314.pdf">Reference Source</a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d7882e3764 class=n-a></a>Public Health England: HPR volume 10 issue 22:news (8July). [cited 2017 Jan 13]. <a target=xrefwindow id=d7882e3766 href="https://www.gov.uk/government/publications/health-protection-report-volume-10-2016/hpr-volume-10-issue-22-news-8-july">Reference Source</a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d7882e3775 class=n-a></a>ICO Information Centre on HPV and Cancer: Human Papillomavirus and Related Diseases Report: Denmark, December 15 2016. <a target=xrefwindow id=d7882e3777 href="http://www.hpvcentre.net/summaryreport.php">Reference Source</a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d7882e3787 class=n-a></a>Blomberg M, Dehlendorff C, Sand C, <i> et al.</i>: Dose-Related Differences in Effectiveness of Human Papillomavirus Vaccination Against Genital Warts: A Nationwide Study of 550,000 Young Girls. <i>Clin Infect Dis.</i> 2015; <b>61</b>(5): 67682. <a target=xrefwindow id=d7882e3798 href="http://www.ncbi.nlm.nih.gov/pubmed/25944340">PubMed Abstract </a> | <a target=xrefwindow id=d7882e3801 href="http://dx.doi.org/10.1093/cid/civ364">Publisher Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d7882e3810 class=n-a></a>Immunisation Scotland: HPV Vaccine. 2016, [cited 2017 Jan 13]. <a target=xrefwindow id=d7882e3812 href="http://www.immunisationscotland.org.uk/vaccines-and-diseases/hpv.aspx">Reference Source</a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a name=d7882e3821 class=n-a></a>Information Services Division Publication Report: HPV Immunisation Statistics Scotland, School year 2015/2016. 2016, [cited 2017 Jan 13]. <a target=xrefwindow id=d7882e3823 href="https://www.isdscotland.org/Health-Topics/Child-Health/Publications/2016-11-08/2016-11-08-HPV-Immunisation-Report.pdf">Reference Source</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 12 Jun 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-866/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-866/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Microbiology and Infectious Diseases, Royal Women&rsquo;s Hospital, Parkville, Victoria, Australia<br/> <sup>2</sup> Department of Microbiology, Royal Children&rsquo;s Hospital, Parkville, Victoria, Australia<br/> <sup>3</sup> Department of Infection and Immunity, Murdoch Childrens Research Institute, Royal Children&rsquo;s Hospital, Victoria, Australia<br/> <sup>4</sup> Department of Obstetrics Gynaecology, University of Melbourne, Parkville, Victoria, Australia<br/> <p> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/6-866/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 12 Jun 2017, 6:866 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.10691.1">https://doi.org/10.12688/f1000research.10691.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden">  2017 Lee Ly and Garland SM. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=11527 data-id=10691 data-downloads="" data-views="" data-scholar="10.12688/f1000research.10691.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/6-866/v1/pdf?article_uuid=2d06b23c-e05e-43da-84b4-ced3fc92334c" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.10691.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Lee Ly and Garland SM. Human papillomavirus vaccination: the population impact [version 1; peer review: 3 approved] <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):866 (<a href="https://doi.org/10.12688/f1000research.10691.1" target=_blank>https://doi.org/10.12688/f1000research.10691.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=10691 id=mobile-track-article-signin-10691 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/10691?target=/articles/6-866/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=11527 /> <input name=articleId type=hidden value=10691 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Eileen Dunne</strong>, Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, USA; HIV/STD Research Program, Thailand MOPH CDC Collaboration, Thailand </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Linda Niccolai</strong>, Yale School of Public Health, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Mark Jit</strong>, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, UK; National Infections Service - Colindale, Public Health England, UK </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 12 Jun 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-866/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-866/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=23010-22834></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=23012-22836></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=23011-22835></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/6-866/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>12 Jun 17</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Eileen Dunne</strong>, Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, USA; HIV/STD Research Program, Thailand MOPH CDC Collaboration, Thailand </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Linda Niccolai</strong>, Yale School of Public Health, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Mark Jit</strong>, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, UK; National Infections Service - Colindale, Public Health England, UK </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/6-866/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/6-866/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Human papillomavirus vaccination: the population...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/6-866/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/6-866/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/6-866/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Lee Ly and Garland SM');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/6-866/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/6-866",
            templates : {
                twitter : "Human papillomavirus vaccination: the population impact. Lee Ly and Garland SM, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/6-866/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Human papillomavirus vaccination: the population impact", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Human papillomavirus vaccination: the population impact", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/10691/11527")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "11527");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "22834": 0,
                           "22835": 0,
                           "22836": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "4115d5a6-2086-4581-8e9a-48310408948b";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-866.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-866.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-866.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/6-866.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/6-866.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>